Our Biologics Production Facility (BPF) provides both early-phase (preclinical) and clinical (Phase 1) current Good Manufacturing Practice, or cGMP, manufacturing capabilities for a range of cellular-based products from eukaryotic and prokaryotic culture systems. These products include monoclonal antibodies, fusion proteins, conjugates, plasmids, viral vectors and peptide vaccines.
Our trained, qualified personnel conduct all manufacturing activities using approved written procedures in accordance with cGMP guidelines. We provide quality assurance oversight and review to ensure regulatory compliance and the safety of therapeutic products.
To start a collaboration with us, review our product management information or contact us at:
This virtual tour takes you inside the Therapeutic Products shared resource’s BPF to learn about the processes, facilities and equipment for producing high-quality biologics for preclinical studies and clinical trials. Highlights:
Go inside the BPF and learn about our work.